HGP1705 clinical trials
Also written HGP1705.
How each study uses HGP1705 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HGP1705
- 3
Studies by the year they started
3 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2020 | 1 |
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Esomeprazole (2) · HIP1802 (1)
Studies
Open first, then newest update. How each study uses HGP1705 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy VolunteersCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT04324905Written as HGP1705
- Efficacy and Safety of HIP1601 CapsuleCompletedPhase 3Hanmi Pharmaceutical Company LimitedNCT04080726Written as HGP1705
- Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole FormulationsStatus unknownPhase 1Hanmi Pharmaceutical Company LimitedNCT03372850Written as HGP1705